Center for Health Market Innovations (CHMI)

Programs

Venture Strategies Innovations (VSI)

last updated Sep 27, 2011

Overview

Implementation Partner(s): 
DKT; EngenderHealth; John Snow INternational; Marie Stopes International; Population Council; Population Services International; Venture Strategies for Health & Development; Private Nurse Midwives Association of Tanzania; Ifakara Health Institute; Ethiopian Nurse Midwives Association; Ethiopian Society of Obstetricians & Gynecologists; Ahmadu Bello University; Associação Moçambicana de Obstetrícia e Ginecologia; Association of Gynecologists and Obstetricians of Tanzania; Bixby Center for Population, Health and Sustainability
Legal Status: 
Year Launched: 
2009
Stage: 
Existing/expansion stage
Income Level of Target Population: 
All income levels

Funding

Primary Source of Funding: 
Donor

Scale

Number of Clients Served: 
ANC providers enrolled more than 3,800 pregnant women on the misoprostol program
Other Measures of Scale: 
Over 500 ANC providers and Community Midwives trained on the use of Misoprostol tablets; 3,000 community health workers have been sensitised to raise awareness of the misoprostol tablets program in the communities
Summary: 

Venture Strategies Innovations is a US-based nonprofit organization committed to improving women's health in developing countries by creating access to life-saving medications for mothers, changing national legislation to be more favorable towards maternal health, and using an innovative task shifting model to empower women and healthcare workers to take on more responsibility in healthcare provision.

Program goals/rationale: 

Over 340,000 women lose their lives in pregnancy and childbirth every year, virtually all of whom are in the developing world. VSI works to increase women's access to vital health services and products.

Key program components: 

VSI aims to improve access to family planning and reproductive health and maternal health in three ways: improving the availability of Misoprostol, a lifesaving drug that can reduce post-birth hemorrhaging; working with governments to incorporate Misoprostol into their national guidelines; and promoting task-shifting and training.

VSI's work with Misoprostol includes ensuring that high-quality versions of the drug are available at an affordable price, planning for the tablets' availability through both commercial and public channels, developing policies to enable their use by different kinds of healthcare providers, and researching alternative modes of distributing the drug at the village level. In addition as of mid-2011, VSI has successfully facilitated the inclusion of misoprostol in national guidelines or essential medicines lists in Ghana, Ethiopia, Tanzania, Zanzibar, Nigeria, Uganda, Zambia and Kenya.

VSI also strives to increase access to family planning by advocating for task shifting. According to VSI, the answer to a lack of properly trained physicians is to broaden the scope of what existing nurses, health workers, volunteers and others are capable of doing. VSI aims to demonstrate that lower level providers - or the woman herself - can administer misoprostol and other drugs crucial to the improvement of maternal health. VSI uses the following guidelines task shifting map.

Need help?

Using the CHMI Programs Database

  • Browse: Browse the database by applying one or more filters to narrow your search by characteristics. Click the "x" to remove any of the filters you've selected. Click "reset search" to remove all filters and start over.
  • Search: Search the database for a specific program by typing a name or keyword into the search box.
  • Add: If the program you're looking for is not in the CHMI database, submit the program to the CHMI pipeline by clicking here to add a program profile.
  • Update: If you notice incorrect or outdated information, or would like to help complete a profile for a CHMI pipeline program, request a change by clicking here, or at the top of the program profile.

Have a question? Check the FAQs first. Don’t see your question? Contact us.